

new  
study

plasma care®

**THE new GOLD STANDARD**

The **FIRST** multicenter, randomized and placebo-controlled study

**10x**  
higher  
Wound Healing

## Accelerated Healing | High Tolerability | Early Pain Reduction

**Innovative, effective & safe therapy**

### Study Title:

Treatment of Chronic Wounds with the plasma care® cold plasma device versus placebo: A multicenter, randomized, single-blind clinical trial

Published in: Journal of Wound Care, Volume 34, Issue 8, August 2025

Authors: Strohal et al.

### Study Design:

Prospective, multicenter, two-arm, randomized controlled trial (RCT). Single-blind.

### Participants

70 patients (18–95 years) with chronic wounds ( $\leq 20 \times 10$  cm; diverse etiologies/stages).

- Plasma group (n=35): plasma care® + standard wound care
- Placebo group (n=35): placebo device + standard wound care

duration of treatment: 6 weeks

### Methodology:

#### Standardized Care Protocol:

- Wound cleansing with 0.9% NaCl
- Phase-appropriate primary dressings (no antimicrobials in CAP group)

#### Frequency:

Application: 60-second treatment per wound area

- Week 1: 3x/week (Mon/Wed/Fri)
- Weeks 2: 2x/week (Mon/Thu)
- Week 3 onward: 1x/week (Mon)

Dressing Changes: Every 2-3 days

#### Endpoint:

**Primary:** Absolute/relative wound area reduction

**Secondary:** pH, pain (VAS), exudate, signs of infection, tolerability

## A clinical MILESTONE in modern WOUNDCARE

**600%**  
higher  
HEALING RATE

**83%**  
reduced  
WOUND EXUDATE

**0**  
adverse  
EVENTS



new  
study

plasma care®

THE new **GOLD STANDARD**

The **FIRST** multicenter, randomized and placebo-controlled study

**2x**  
faster  
Wound  
Reduction

**Accelerated Healing | High Tolerability | Early Pain Reduction**

#### Key Findings:

##### 1. Wound Healing Dynamics:

- **54,3% complete wound healing with CAP** vs. 5.7% with placebo at Day 28
- **600% higher healing rate with CAP** in only 28 days
- **Wound area reduction: 0.7cm<sup>2</sup>/visit (CAP)** vs. 0,35cm<sup>2</sup>/visit (placebo)

##### 2. Wound Environment:

- **pH normalization:** 7.73 (CAP) vs. 9.11 (placebo)
- **Exudate reduction:** 83% of CAP patients achieved „low/no“ exudate vs. 17% (placebo)

##### 3. Patient Outcomes:

- **Significant pain reduction** (VAS) from 3rd CAP treatment
- **100% tolerability** - no device-related adverse events

#### Conclusion:

plasma care® enables significantly **faster wound closure, accelerating recovery** versus standard care. **Higher reduction in exudate** minimizes dressing frequency and nursing workload, **saving time and costs**. Effective **pain relief** from early treatments improves **patient compliance** and comfort. Optimized wound environment lowers infection risks while demonstrating **excellent safety**. This evidence-based treatment option delivers superior clinical outcomes efficiently, elevating therapeutic standards across care settings.

The evidence supports **plasma care®** as an effective plus to standard wound care.

